Sustainability | February 20, 2024
Biocon included in S&P Global Sustainability Yearbook 2024
Sustainability is integral to Biocon's business purpose
Sustainability is integral to Biocon's business purpose
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Over 34 lakh children and 6 lakh pregnant women were administered vaccine doses during the first 2 rounds of IMI 5.0 campaign across the country
JB Pharma reported 19% decrease in GHG intensity as compared to last year and commenced its journey of Scope 3 emissions
The biopharmaceutical leader shared its expert perspective at the Equality Lounge at the G20 Summit
The survey findings for Delhi-NCR revealed that speech sound disorders exhibit higher prevalence rates in the 6-12 years age group
Subscribe To Our Newsletter & Stay Updated
